MUST CANADA BECOME THE DRUGSTORE TO THE WORLD?

James Kobak and Jeremy De Douhet
Additional contact information
James Kobak: Hughes Hubbard & Reed LLP
Jeremy De Douhet: Formerly Hughes Hubbard & Reed LLP Foreign Associate

No 1038, International Trade and Finance Association Conference Papers from International Trade and Finance Association

Abstract: This paper examines developments affecting the controversial and important issue of gray market importation of patented and branded pharmaceutical products, particularly developments in Europe, Canada and the United States. Issues considered include the doctrine of exhaustion of intellectual property, which has implications for the ability of intellectual property rights holders to prevent importation of goods first sold abroad (gray market goods). The ability of rights holders to prevent such imports in turn has implications for international trade. Presented at the 15th International Conference, Istanbul, Turkey, May 2005.

Date: 2005-05-18
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bep:itfapp:1038

Access Statistics for this paper

More papers in International Trade and Finance Association Conference Papers from International Trade and Finance Association
Bibliographic data for series maintained by Christopher F. Baum ().